Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 49 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Bristol Myers Squibb, Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
- Tags
- Monoclonal Antibody, SLAMF7, Post-CAR T
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1968
- NCT Identifier
- NCT06518551
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.